Europe South Asia Asia Pacific Americas Middle East Africa BBC Homepage World Service Education

Front Page



UK Politics







Talking Point

In Depth

On Air

Low Graphics

Tuesday, November 16, 1999 Published at 15:53 GMT


Cannabis trials 'encouraging'

Cannabis is thought to relieve the symptoms of a range of conditions

The first ever UK trials of the medicinal impact of cannabis have shown that the drug is unlikely to cause patients any harm.

And scientists have found that the therapeutic effects can be gained without any need to "get high".

GW Pharmaceuticals is growing thousands of cannabis plants under a special Home Office licence with the ultimate aim of developing prescription medicines based on extracts of the drug.

Anecdotal evidence suggests that compounds extracted from the drug could benefit sufferers of multiple sclerosis, spinal cord injury, arthritis and chronic fatigue syndrome as well as a number of other problems.

The initial trials involved testing the impact of cannabis on six healthy volunteers. Much larger trials on ill patients are planned.

Dr Geoffrey Guy, the company chairman, said: "All the subjects came through very well, and we were very pleased with the study.

"Now we have a much better idea of what our starting point should be."

The results of the trial, conducted at an anonymous clinical pharmacology unit, will not be made public until they are disclosed in a scientific journal.

Many could be helped

But GW Pharmaceuticals has revealed that volunteers were given cannabis extracts either from an inhaler or via liquid under the tongue.

The main aim was to assess how well the treatments were tolerated and obtain an initial idea of the optimum dosage.

Heart rate, temperature and respiration were monitored and blood samples taken for analysis.

In addition each volunteer went through a battery of psychological tests.

Dr Guy said: "We have been able to define and follow through the psychoactive effects.

"None of the effects is disturbing, or would be classed in a clinical trial as serious."

He said patients did not need to "get high" to gain a therapeutic benefit.

If approved by the regulatory authorities, the second phase trials will begin next year.

They will involve up to 300 patients with MS, spinal cord injury, and phantom limb pain.

By the end of the final phase three trials a total of around 2,000 patients will have taken part. The main studies should be completed in 2002.

GW Pharmaceutical's cannabis plants are housed in a highly secure and environmentally controlled glasshouse at a secret location in the home counties.

The company hopes to produce cannabis treatments mainly to relieve pain and dysfunction caused by nerve damage.

Advanced options | Search tips

Back to top | BBC News Home | BBC Homepage | ©

Health Contents

Background Briefings
Medical notes

Relevant Stories

22 Jul 99 | Health
Medicinal cannabis grower acquitted

09 Jul 99 | Health
Cannabis therapy man escapes jail

08 Jul 99 | Health
BMA rejects legalisation of cannabis

21 Jun 99 | Health
New call for cannabis reform

04 Jun 99 | Health
International interest in marijuana inhaler

25 Mar 99 | Health
'Natural marijuana' may treat brain disorders

13 Jan 99 | Health
Doctors volunteer for cannabis trials

05 Jan 99 | Health
Cannabis grown for medical tests

Internet Links

Campaign to Legalise Cannabis International Association

Home Office

Cannabis News

The BBC is not responsible for the content of external internet sites.

In this section

Disability in depth

Spotlight: Bristol inquiry

Antibiotics: A fading wonder

Mental health: An overview

Alternative medicine: A growth industry

The meningitis files

Long-term care: A special report

Aids up close

From cradle to grave

NHS reforms: A guide

NHS Performance 1999

From Special Report
NHS in crisis: Special report

British Medical Association conference '99

Royal College of Nursing conference '99